Second line of therapy for gastrointestinal stromal tumors: is there a choice?-Reference-Cited by-同舟云学术

Second line of therapy for gastrointestinal stromal tumors: is there a choice?

Published:2019-06-24 Issue:10 Volume: Page:28-36
ISSN:2658-5790
Container-title:Medical Council
language:
Short-container-title:Med. sov.

Author:

Kogonia L. M.¹,Koroleva A. M.²

Affiliation:

1. «Reaviz» Medical University.

2. State Budgetary Healthcare Institution of the Moscow Region «Vladimirsky Moscow Regional Research Clinical Institute».

Abstract

Gastrointestinal stromal tumors (GISTs) are rare mesenchymal tumors. Currently, it is possible to carry out three consecutive lines of target therapy against metastatic GISTs: imatinib as first-line, sunitinib as second line and regorafenib as third line. The mutation status of the C-Kit gene is a predictor of GIST sensitivity to imatinib and sunitinib. Some patients have to stop the treatment due to sunitinib related toxicity. Regorafenib can be used as the second line therapy of metastatic GISTs in case of sunitinib intolerance.

Publisher

Remedium, Ltd.

Subject

General Medicine

Reference82 articles.

1. Sakurai S., Fukasawa T., Chong J. et al. C-kit gene abnormalities in gastrointestinal stromal tumors. Jpn. J. Cancer Res. 1999;90:1321-1328.

2. Mazur M., Clark H. Gastric stromal tumors: R=re appraisal of histogenesis. Am. J. Surg. Pathol. 1983;7:507-519.

3. Sarlomo-Rikala M., Kovatich A., Barusevicius A. et al. CD117: A sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathology. 1998;11:728-734.

4. Demetri G., Benjamin R., Blanke C. et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST) – update of the NCCN clinical practice guidelines. J. Natl. Compr. Canc. Netw. 2007;5(Suppl. 2):S1-S29.

5. Kindblom L.G., Remotti H.E., Aldenborg F. et al. Gastrointestinal pacemaker cell tumor: Gasrtrointestinal stromal tumors show phenotypic characteristics of the intestinal cells of Cajal. Am J Pathology. 1998;152:1259-1269.